Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$27.95 USD
+0.28 (1.01%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $27.98 +0.03 (0.11%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Brokerage Reports
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 221 - 240 ( 245 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
F3Q11 Results Review: Lots to Like: Growth, Acquisition, and European Expansion
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Incremental Growth Drivers Lead Us to Increase Estimates and Price Target
Provider: AURIGA USA
Analyst: MEHRA R
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Lab Industry Alert: Attending 28th Annual Lab Institute 2010 Conference.
Provider: KAUFMAN BROTHERS
Analyst: BROCK D
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
In Today''s Morning Exchange
Provider: KAUFMAN BROTHERS
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
What could be the Impact on Diagnostic Companies from a Re-Invigorated FDA?
Provider: AURIGA USA
Analyst: MEHRA R
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
The Bar Has Been Reset - Upgrading Rating to BUY and Increasing Price Target to $23
Provider: AURIGA USA
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
F3Q10 Results Review: Too Many Headwinds.
Provider: AURIGA USA